Home The Word Brain My Amedeo FAQ Privacy About   


Explore this week’s CC Journal Club

90‑sec video • 4‑min audio • paper abstracts


  HIV Infection

  Free Subscription


Articles published in Antivir Ther

Retrieve available abstracts of 6 articles:
HTML format



Single Articles


    April 2025
  1. ELEJE GU, Usman HA, Onubogu CU, Fiebai PO, et al
    Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort study.
    Antivir Ther. 2025;30:13596535251333259.
    PubMed     Abstract available


  2. PALLANZA M, Thoueille P, Briki M, Alves Saldanha S, et al
    Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine.
    Antivir Ther. 2025;30:13596535251335080.
    PubMed     Abstract available


  3. LABATE L, Rossetti B, Russo C, Cassol C, et al
    Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database.
    Antivir Ther. 2025;30:13596535251317054.
    PubMed     Abstract available


    February 2025
  4. PICKERING RT, Asundi A, Olson A, Soden K, et al
    Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir.
    Antivir Ther. 2025;30:13596535251314571.
    PubMed     Abstract available


    December 2024
  5. PASSEROTTO RA, Lamanna F, Salvo PF, Iannone V, et al
    Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort.
    Antivir Ther. 2024;29:13596535241306467.
    PubMed     Abstract available


    April 2024
  6. VAN HEMELRYCK S, Van Landuyt E, Hufkens V, Vanveggel S, et al
    Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged >/=6 to <12 years, using matching placebo tablets: A ran
    Antivir Ther. 2024;29:13596535241248282.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.